Table 4 Comparison of the mean HER2 gene copy number and the HER2/CEP17 ratio on the HERA screening population

From: Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data

 

Gene count positive (≥6)

Gene count equivocal (4–6)

Gene count negative (<4)

Total

Ratio positive (>2.2)

2922

374

43

3339

Ratio equivocal (1.8– 2.2)

13

17

14

44

Ratio negative (<1.8)

17

103

2515

2635

Total

2952

494

2572

6018

  1. Numbers represent amount of patients.
Back to article page